| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Tanvex BioPharma Inc (TW: 6541)
6541 Technical Analysis
4
| As on 13th Oct 2025 6541 STOCK Price closed @ 63.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 60.76 & Strong Buy for SHORT-TERM with Stoploss of 43.62 we also expect STOCK to react on Following IMPORTANT LEVELS. |
6541STOCK Price
| Open | 58.00 | Change | Price | % |
| High | 63.80 | 1 Day | 5.80 | 10.00 |
| Low | 56.70 | 1 Week | 12.10 | 23.40 |
| Close | 63.80 | 1 Month | 9.60 | 17.71 |
| Volume | 6465838 | 1 Year | 16.60 | 35.17 |
| 52 Week High 81.80 | 52 Week Low 36.95 | ||||
TW Taiwan Most Active Stocks
| 2888 | 11.80 | 3.96% |
| 2344 | 43.00 | -1.04% |
| 2408 | 95.60 | -2.94% |
| 1605 | 30.90 | -4.33% |
| 2317 | 213.00 | -3.84% |
| 1802 | 30.55 | -3.78% |
| 3706 | 96.40 | 0.94% |
| 3481 | 15.25 | -1.61% |
| 2887 | 18.55 | -1.33% |
| 2409 | 13.55 | -3.21% |
TW Taiwan Top Gainers Stocks
TW Taiwan Top Losers Stocks
| 6541 Daily Charts |
6541 Intraday Charts |
Whats New @ Bazaartrend |
6541 Free Analysis |
|
|
6541 Important Levels Intraday
| RESISTANCE | 77.48 |
| RESISTANCE | 73.09 |
| RESISTANCE | 70.38 |
| RESISTANCE | 67.67 |
| SUPPORT | 59.93 |
| SUPPORT | 57.22 |
| SUPPORT | 54.51 |
| SUPPORT | 50.12 |
6541 Forecast October 2025
| 4th UP Forecast | 82.49 |
| 3rd UP Forecast | 76.5 |
| 2nd UP Forecast | 72.79 |
| 1st UP Forecast | 69.09 |
| 1st DOWN Forecast | 58.51 |
| 2nd DOWN Forecast | 54.81 |
| 3rd DOWN Forecast | 51.1 |
| 4th DOWN Forecast | 45.11 |
6541 Weekly Forecast
| 4th UP Forecast | 72.09 |
| 3rd UP Forecast | 69.43 |
| 2nd UP Forecast | 67.79 |
| 1st UP Forecast | 66.14 |
| 1st DOWN Forecast | 61.46 |
| 2nd DOWN Forecast | 59.81 |
| 3rd DOWN Forecast | 58.17 |
| 4th DOWN Forecast | 55.51 |
6541 Forecast2025
| 4th UP Forecast | 154.27 |
| 3rd UP Forecast | 125.26 |
| 2nd UP Forecast | 107.32 |
| 1st UP Forecast | 89.39 |
| 1st DOWN Forecast | 38.21 |
| 2nd DOWN Forecast | 20.28 |
| 3rd DOWN Forecast | 2.34 |
| 4th DOWN Forecast | -26.67 |
Tanvex BioPharma Inc ( TW Taiwan Symbol : 6541 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
6541 Business Profile
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. The company's lead product candidate includes TX01 for the treatment of neutropenia. It also develops TX05, which has completed phase III clinical trial for the treatment of breast cancer; TX04 for the treatment of neutropenia; TX16 that has completed phase I clinical trial for the treatment of metastatic colorectal cancer; TX52, which is in pre-clinical trial; and other products. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. Address: 802 West Bay Road, George Town, Cayman Islands, KY1-1205
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service